Written Question · S4W-02856 · Session 4
For what reason transcatheter aortic valve implantation is available as an NHS treatment in England, Wales and Northern Ireland but not in …
The question
To ask the Scottish Executive for what reason transcatheter aortic valve implantation is available as an NHS treatment in England, Wales and Northern Ireland but not in Scotland.
The answer
We are keen that people in Scotland should have ready access to new treatments and technologies once they have demonstrated their effectiveness.
The most recent review of TAVI found that there was limited evidence to support its introduction in Scotland however.
The National Institute for Health and Clinical Excellence (NICE) is currently consulting on draft Interventional Procedures Programme (IPP) guidance on the safe and efficacious use of TAVI in the UK. The guidance is expected to be made available in November 2011.
The National Institute for Health Research has also commissioned a Health Technology Assessment (HTA) looking at cost effectiveness, which is due to be published in December 2011.
NHSScotland will take this emerging evidence into account in its future consideration of the provision TAVI.
Meantime, we expect that NHS boards should continue to ensure that local arrangements are in place so that people with severe aortic stenosis get access to appropriate clinical treatment. As part of those arrangements, where it is considered clinically appropriate by their doctors, patients can get access to TAVI treatment through consideration by an individual case panel.
The most recent review of TAVI found that there was limited evidence to support its introduction in Scotland however.
The National Institute for Health and Clinical Excellence (NICE) is currently consulting on draft Interventional Procedures Programme (IPP) guidance on the safe and efficacious use of TAVI in the UK. The guidance is expected to be made available in November 2011.
The National Institute for Health Research has also commissioned a Health Technology Assessment (HTA) looking at cost effectiveness, which is due to be published in December 2011.
NHSScotland will take this emerging evidence into account in its future consideration of the provision TAVI.
Meantime, we expect that NHS boards should continue to ensure that local arrangements are in place so that people with severe aortic stenosis get access to appropriate clinical treatment. As part of those arrangements, where it is considered clinically appropriate by their doctors, patients can get access to TAVI treatment through consideration by an individual case panel.
In the Official Report
No contribution in the Official Report cites S4W-02856 by reference.